Abstract:Introduction: Worldwide, endometrial cancer (EC) is the most common gynecological malignancy with increasing rate of incidence and mortality. While progesterone-based hormone therapy is a well-accepted conservative therapeutic option for EC patients, loss of progesterone receptor (PR) in long-term treatment leading to hormonal resistance and disease recurrence is still an area of concern. We demonstrated potent anti-cancerous activity of sulforaphane against EC in vitro and in vivo and hypothesized that it will activate PR and overcome progesterone therapy limitations. The purpose of this study was to evaluate the interaction of sulforaphane and progesterone against EC. Methods: The in vitro synergistic interaction between sulforaphane and progesterone was investigated with isobologram analysis of plotting MTT metabolic viability assay results of EC cells treated with drugs individually and in combination using CompuSyn software. ATP, soft-agar colony formation and invasion assays were performed to evaluate the combined drug effects on cell viability, anchorage independent colony formation and invasion properties, respectively. Mitochondrial membrane potential and caspase-3 activity were measured by JC-1 and caspase-3 detection ELISA kit, respectively. Protein expression was accessed by western blot. Progesterone resistant EC cells were developed by treating cells with 30μM of progesterone for more than 3 months. Results: Sulforaphane demonstrated strong synergy or additive effects with progesterone in the EC cell lines tested. Sulforaphane in combination with progesterone significantly decreased levels of cellular ATP, anchorage-independent colony formation, invasion and mitochondrial membrane potential. Furthermore, combination of sulforaphane and progesterone increased caspase-3 activity as compared to individual drug or controls, suggesting induction of apoptosis. Western blot results demonstrated an increased expression of cleaved PARP, with reduced expression of total caspase-3 and PCNA in the combination groups as compared to control and individual drugs. Sulforaphane alone or in combination showed increased expression of PR-A while it had minimal effects on PR-B. Further, in all EC cell lines, the combination of sulforaphane and progesterone demonstrated upregulation of PR-A/PR-B ratio. The progesterone resistant cells demonstrated less sensitivity to progesterone as compared to parent cell lines, however it was found to be sensitive to sulforaphane. Conclusions: Sulforaphane demonstrated synergistic activity with progesterone leading to increased apoptosis and reduced proliferation. Furthermore, sulforaphane exhibited potent toxicity to progesterone resistance cells. Sulforaphane in combination with progesterone could overcome progesterone therapy limitation by re-activation of PR. Funding: Administrative Suppl (P30CA225520) and PHF (GRF00005456) Citation Format: Rajani Rai, Swati Choudhary, Doris M. Benbrook, Vishal Chandra. Synergistic efficacy of sulforaphane and progesterone against endometrial cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5951.

Progesterone inhibits endometrial cancer growth by inhibiting glutamine metabolism through ASCT2

Glutamine and amino acid metabolism as a prognostic signature and therapeutic target in endometrial cancer

Involvement of Cyclin B1 in Progesterone-Mediated Cell Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Endometrial Cell

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5′-monophosphate (AMP)-activated protein kinase signaling pathway

Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy

Abstract B009: Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets

Genistein induces long-term expression of progesterone receptor regardless of estrogen receptor status and improves the prognosis of endometrial cancer patients

Estrogen Inhibits Autophagy and Promotes Growth of Endometrial Cancer by Promoting Glutamine Metabolism

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Metformin Promotes Progesterone Receptor Expression Via Inhibition of Mammalian Target of Rapamycin (mtor) in Endometrial Cancer Cells

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer

Gefitinib Enhances Sensitivity of Endometrial Cancer Cells to Progestin Therapy Via Dual-Specificity Phosphatase 1.

Abstract 5951: Synergistic efficacy of sulforaphane and progesterone against endometrial cancer

Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer

Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis

Targeting GRP75 with a Chlorpromazine Derivative Inhibits Endometrial Cancer Progression Through GRP75–IP3R‐Ca2+‐AMPK Axis

MG132-mediated Suppression of the Ubiquitin-proteasome Pathway Enhances the Sensitivity of Endometrial Cancer Cells to Cisplatin

Fertility-sparing treatment in women with endometrial cancer

Inhibiting 3βhsd1 to Eliminate the Oncogenic Effects of Progesterone in Prostate Cancer